PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Beclometasone dipropionate - Allergic rhinitis

PAD Profile : Beclometasone dipropionate - Allergic rhinitis

Keywords :
Hay fever, hayfever, antihistamines, nasal sprays, allergy, seasonal allergic rhinitis, intranasal corticosteroids, pollen allergy, INCS, non-sedating antihistamines
Brand Names Include :
Beconase, Nasobec

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important Preferred
Formulations :
  • Nasal spray
Important Information :
Beconase Aqueous 200 dose container is the most cost effective nasal steroid spray for primary care. NOTE Beconase Hayfever and other container sizes (180 dose and 100 dose) are much more expensive and should not be used.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date
Guidelines (Local)
01 January 2024

Committee Recommendations

Date
Committee Name
Narrative
04 May 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Beconase 200 dose nasal spray or generic beclometasone 200 dose nasal sprays are the preferred intranasal corticosteroid for allergic rhinitis. NOTE - Beconase Hayfever / beclometasone 100 and 180 dose containers are considerably more expensive and should not be used

Associated BNF Codes

12. Ear, Nose and Oropharynx
12.02.01. Drugs used in nasal allergy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More